IDH2 and acute myeloid leukemia: Interestingly, mutations in IDH2 had a positive impact on the survival of total NK AML patients’ population treated with DAC (54% vs 33% for IDH2+ vs IDH2−, p = 0.0087) but not DA (21% vs 23% for IDH2+ vs IDH2−, p = 0.22) regimen, after censoring at alloHSCT (Fig. 2, Supplemental Fig. S2).